Bruker Corporation Investor Day 2023
INVESTOR DAY 2023
Bruker transformation accelerates value-creation for all stakeholders
■
2014-2016: RESTRUCTURING &
TRANSFORMATION PHASE
■
Organic Revenue CAGR
8% 8%
■
2%
2012-18
G = guidance midpoint
■ Cost out, consolidation and divestitures
New organization & management process
Integrated ERP, SF CRM adoption
New HR compensation/incentives
Increased outsourcing
2023 Bruker
2018-23G
■
2017-2020: PROJECT ACCELERATE
& OPERATIONAL EXCELLENCE
■
Non-GAAP EPS CAGR
13%
9%
11
Portfolio transformation
Entrepreneurial Bruker Management Process
Improved productivity
■ Shared services centers
Enhanced compliance & risk management
■
2012-18
■
2018-23G
2018-2022
■
2021-202X: PROJECT ACCELERATE 2.0
& OPERATIONAL EXCELLENCE
Major focus Proteomics and Spatial Biology
Microbiology & Molecular DX
■
■
ROIC
>20%
■
■
BRUKER
Biopharma & Applied, Semi Metrology
Aftermarket, Consumables & Software
Further improved productivity, tax rate, FCF
Innovation with Integrity
June 15, 2023 I 9View entire presentation